These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33505906)

  • 1. Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer.
    Lee JS; Yost SE; Yuan Y
    Front Oncol; 2020; 10():582185. PubMed ID: 33505906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.
    Yuan Y; Lee JS; Yost SE; Frankel PH; Ruel C; Egelston CA; Guo W; Gillece JD; Folkerts M; Reining L; Highlander SK; Robinson K; Padam S; Martinez N; Tang A; Schmolze D; Waisman J; Sedrak M; Lee PP; Mortimer J
    Oncologist; 2021 Feb; 26(2):99-e217. PubMed ID: 33141975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer.
    Chen TH; Chang PM; Yang MH
    J Chin Med Assoc; 2021 Apr; 84(4):361-367. PubMed ID: 33496513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
    Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
    Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable Response to Programmed Death 1-Directed Antibodies in a Hypermutated Triple-Negative Breast Cancer: A Case Report.
    Platteter E; Wulf G
    Case Rep Oncol; 2024; 17(1):392-398. PubMed ID: 38435448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer.
    Mimura K; Shimomura A; Gota T; Ando K; Kawamura Y; Taniyama T; Oishi H; Shimizu C
    Gynecol Oncol Rep; 2022 Dec; 44():101084. PubMed ID: 36277029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
    Varma R; Wright M; Abraham J; Kruse M
    Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer.
    Cipriano É; Mesquita A
    Breast Cancer (Auckl); 2021; 15():11782234211002491. PubMed ID: 33814914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer.
    Zheng C; Zhang W; Wang J; Zhai Y; Xiong F; Cai Y; Gong X; Zhu B; Zhu HH; Wang H; Li Y; Zhang P
    Acta Pharm Sin B; 2022 Sep; 12(9):3726-3738. PubMed ID: 36176911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term response to sintilimab, bevacizumab and chemotherapy in heavily pretreated microsatellite stable colon cancer.
    Cui Z; Wang Q; Deng M; Meng E; Liu S; Niu B; Han Q
    Immunotherapy; 2023 Feb; 15(3):127-133. PubMed ID: 36722149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
    Liang X; Chen X; Li H; Li Y
    Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Immunotherapy in the Treatment of Triple-Negative Breast Cancer: A Literature Review.
    K Patel K; Hassan D; Nair S; Tejovath S; Kahlon SS; Peddemul A; Sikandar R; Mostafa JA
    Cureus; 2022 Nov; 14(11):e31729. PubMed ID: 36569674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
    Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
    Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Retreatment of Metastatic Triple-negative Breast Cancer With Immune Checkpoint Inhibitors and Chemotherapy.
    Nozaki Y; Yamamuro M; Tanaka N; Kamo N; Konishi J
    Cancer Diagn Progn; 2023; 3(3):387-391. PubMed ID: 37168973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population.
    Fujiwara R; Yuasa T; Kobayashi K; Yoshida T; Kageyama S
    Expert Rev Anticancer Ther; 2023 May; 23(5):461-469. PubMed ID: 37038721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges.
    Uchimiak K; Badowska-Kozakiewicz AM; Sobiborowicz-Sadowska A; Deptała A
    Clin Med Insights Oncol; 2022; 16():11795549221099869. PubMed ID: 35721387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent response of refractory triple-negative breast cancer to sintilimab plus chemotherapy: a case report.
    Yao G; Huang J; Zhang Q; Hu D; Yuan F; Han G
    Immunotherapy; 2023 Mar; 15(4):221-228. PubMed ID: 36789554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: Hypertriglyceridemia-Induced Pancreatitis after Lenvatinib and Pembrolizumab Use.
    Sultan K; Khan Z; Saadat S
    Case Rep Oncol; 2024; 17(1):311-316. PubMed ID: 38390453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors.
    Naik A; Decock J
    Front Oncol; 2020; 10():598626. PubMed ID: 33324565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.